First gene therapy to treat rare blood disease nears European approval
The first gene therapy to treat a rare blood disorder is one step closer to approval following a positive regulatory action taken by European officials.
by Adam Feuerstein
Mar 29, 2019
2 minutes
The first gene therapy to treat a rare blood disorder is one step closer to approval Friday following a recommendation by European officials.
Lentiglobin, the developed by Cambridge, Mass.-based Bluebird Bio, was recommended for approval by the Committee for Medicinal Products for Human Use (CHMP), the drug-reviewing arm of
You’re reading a preview, subscribe to read more.
Start your free 30 days